🧪The lesser-known biotech company IGM Biosciences creating therapeutics for several cancer indications topped our Rippers list today. $IGMS soared over 58% today after presenting preliminary data from a very early-stage clinical trial. This prompted Stifel to sound a bullish price target and send a surge of new money into the stock. The company announced their intention to use the excitement around the stock to raise another round of funding. Despite the announcement of the raise, the stock is up 80% this week.

🛍We’ve seen a bunch of e-commerce companies taking off over the last few months because of the pandemic. Today’s e-commerce all-star is one you’ve probably never heard of: Liquidity Services. $LQDT is one place where all of the returned and excess products end up. The company owns several online auction marketplaces where you can buy pallets of liquidated items, second-hand stock and even government assets. It might be one of the strangest places on the internet to shop. The company is up 41% today and 156% this year.

👕A more ‘normal’ e-commerce company comes in the form of premium personal styling service Stitch Fix, which soared nearly 50% in trading today. $SFIX indicated that their sales returned to pre-COVID levels in the third quarter. The company reported a 10% year-over-year growth in revenue and active users, which translated to the company adding some 240,000 new customers in the quarter.

Author Profile Picture

Noah Weidner

Noah Weidner is a restless self-starter with a vehement interest in all things that make the world go around: culture, politics, economics and all the people in between. He writes the Bullish Rippers series and covers other interesting trends and happenings at Bullish.

What Did You Think?

Join The Discussion

Be the first to Comment!


Leave your comment:

Stocks Mentioned

IGM Biosciences logo

IGM Biosciences, a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer.The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies.It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies.IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies.The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. (From: StockAnalysis.com)